Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Appetite and Promotes Weight Loss in Patients With Type 2 Diabetes (T2D): Phase 3 Trial Versus Sitagliptin and Placebo (T-Emerge 4)

被引：0

作者：

Bergenstal, Richard

Forti, Adriana

Chiasson, Jean-Louis

Woloschak, Mike

Boldrin, Mark

Leiter, Lawrence

Balena, Raffaella

机构：

来源：

OBESITY | 2010年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S156 / S156

页数：1

共 50 条

[1] Once Weekly Taspoglutide, a Human GLP-1 Analog, Is Superior to Sitagliptin in Improving Glycemic Control and Weight Loss in Patients with Type 2 Diabetes (T2D): Results from the T-emerge 4 Trial
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence A.
Balena, Raffaella
DIABETES, 2010, 59 : A16 - A16
[2] Taspoglutide, a once-weekly human GLP-1 analogue, is superior to Sitagliptin in improving glycaemic control and achieving weight loss in patients with type 2 diabetes: the T-emerge 4 Trial
Chiasson, J. -L
Leiter, L. A.
Forti, A.
Bergenstal, R. M.
Woloschak, M.
Boldrin, M.
Balena, R.
DIABETOLOGIA, 2010, 53
[3] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Body Weight, Waist and Hip Circumferences, and Decreases Appetite When Used as Monotherapy in Type 2 Diabetes (T2D): Results From the T-Emerge 1 Trial
Raz, Itamar
Fonseca, Vivian
Kipnes, Mark
Durrwell, Laurence
Hoekstra, John
Boldrin, Mark
Balena, Raffaella
OBESITY, 2010, 18 : S154 - S154
[4] Taspoglutide, a Once-Weekly Human GLP-1 Analog, as Monotherapy Significantly Lowers A1c and Body Weight in Patients with Type 2 Diabetes (T2D): Results from the T-Emerge 1 Phase 3 Trial
Raz, Itamar
Fonseca, Vivian
Kipnes, Mark
Durrwell, Laurence
Hoekstra, John
Boldrin, Mark
Balena, Raffaella
DIABETES, 2010, 59 : A107 - A107
[5] Taspoglutide, a Once-Weekly (QW) Human GLP-1 Analog, Reduces Body Weight, Waist and Hip Circumferences, and Decreases Appetite in Patients With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin +/- Thiazolidinedione: Results From the Phase 3 T-Emerge 2 Trial
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark
Ratner, Robert
Balena, Raffaella
OBESITY, 2010, 18 : S51 - S52
[6] Once-Weekly Taspoglutide, a Human GLP-1 Analog, Is Superior to Placebo in Improving Glycemic Control and Body Weight Loss in Obese Patients with Type 2 Diabetes (T2D) Inadequately Controlled with Metformin Monotherapy: Results from the T-emerge 7 Trial
Hollander, Priscilla
Bengus, Monica
Barnett, Anthony
Lasko, Ben
Boldrin, Mark
Balena, Raffaella
Pi-Sunyer, F. Xavier
DIABETES, 2010, 59 : A160 - A160
[7] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Body Weight, Waist and Hip Circumferences, and Decreases Appetite in Obese Patients With Type 2 Diabetes (T2D): Results From the Phase 3T-Emerge 7Trial
Hollander, Priscilla
Bengus, Monica
Barnett, Anthony H.
Lasko, Ben
Boldrin, Mark
Pi-Sunyer, F. Xavier
Balena, Raffaella
OBESITY, 2010, 18 : S155 - S155
[8] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Provides Comparable Glycemic Control to Insulin Glargine,' with Superior Weight Loss and Less Hypoglycemia in Type 2 Diabetes (T2D): A Phase 3, Open-Label Trial (T-emerge 5)
Nauck, Michael
Horton, Edward
Andjelkovic, Mirjana
Javier Ampudia-Blasco, F.
Boldrin, Mark N.
Balena, Raffaella
DIABETES, 2010, 59 : A16 - A16
[9] Taspoglutide, a once-weekly human GLP-1 analog, as monotherapy significantly lowers HbA1c and body weight in patients with type 2 diabetes: results from the T-emerge 1 phase 3 trial
Raz, I.
Fonseca, V. A.
Kipnes, M. S.
Durrwell, L.
Hoekstra, J.
Boldrin, M.
Balena, R.
DIABETOLOGIA, 2010, 53
[10] Taspoglutide Reduces Appetite and Promotes Weight Loss in Patients With Inadequately Controlled Type 2 Diabetes: T-Emerge 5, a Phase 3 Trial Versus Insulin Glargine
Nauck, Michael
Horton, Edward
Parusel, Christine T.
Andjelkovic, Mirjana
Javier Ampudia-Blasco, F.
Boldrin, Mark
Balena, Raffaella
OBESITY, 2010, 18 : S155 - S155

← 1 2 3 4 5 →